Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:INSP NASDAQ:LQDA NASDAQ:PRCT OTCMKTS:WEDXF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINSPInspire Medical Systems$93.86+2.6%$113.86$73.92▼$225.00$2.77B1.221.73 million shs656,389 shsLQDALiquidia Technologies$27.68+0.8%$18.89$8.75▼$28.82$2.38B0.143.12 million shs2.17 million shsPRCTPROCEPT BioRobotics$40.17-0.4%$50.64$37.12▼$103.81$2.23B1.051.31 million shs769,202 shsWEDXFWestaim$20.15-0.3%$21.73$16.62▼$25.98$676.13M0.232,945 shs2,980 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINSPInspire Medical Systems0.00%-2.02%-24.63%-32.00%-48.77%LQDALiquidia Technologies0.00%+3.13%+48.10%+84.17%+190.15%PRCTPROCEPT BioRobotics0.00%-2.57%-17.19%-31.45%-49.79%WEDXFWestaim0.00%-3.13%-7.61%-14.26%+585.37%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationINSPInspire Medical Systems4.9827 of 5 stars4.34.00.04.84.11.73.1LQDALiquidia Technologies3.5732 of 5 stars3.53.00.00.03.54.20.6PRCTPROCEPT BioRobotics3.4982 of 5 stars4.41.00.00.04.22.50.6WEDXFWestaimN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINSPInspire Medical Systems 2.54Moderate Buy$165.6276.44% UpsideLQDALiquidia Technologies 3.00Buy$32.1116.01% UpsidePRCTPROCEPT BioRobotics 2.78Moderate Buy$74.8886.40% UpsideWEDXFWestaim 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest WEDXF, INSP, LQDA, and PRCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/15/2025INSPInspire Medical SystemsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Perform ➝ Market Perform$116.00 ➝ $97.008/15/2025LQDALiquidia TechnologiesJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$43.008/13/2025LQDALiquidia TechnologiesRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetStrong-Buy ➝ Strong-Buy$33.00 ➝ $41.008/13/2025LQDALiquidia TechnologiesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$25.00 ➝ $31.008/12/2025LQDALiquidia TechnologiesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$32.00 ➝ $36.008/7/2025PRCTPROCEPT BioRoboticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$75.00 ➝ $58.008/7/2025PRCTPROCEPT BioRoboticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$80.00 ➝ $55.008/5/2025INSPInspire Medical SystemsLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$270.00 ➝ $150.008/5/2025INSPInspire Medical SystemsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$174.00 ➝ $101.008/5/2025INSPInspire Medical SystemsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$270.00 ➝ $230.008/5/2025INSPInspire Medical SystemsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$215.00 ➝ $180.00(Data available from 8/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINSPInspire Medical Systems$802.80M3.46$1.71 per share54.83$22.92 per share4.10LQDALiquidia Technologies$14M170.21N/AN/A$0.18 per share153.78PRCTPROCEPT BioRobotics$224.50M9.96N/AN/A$6.93 per share5.80WEDXFWestaim$17.04M39.69N/AN/A$23.28 per share0.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINSPInspire Medical Systems$53.51M$1.7354.2629.152.926.17%10.38%8.93%11/3/2025 (Estimated)LQDALiquidia Technologies-$130.39M-$1.70N/AN/AN/A-732.17%-232.96%-60.81%11/12/2025 (Estimated)PRCTPROCEPT BioRobotics-$91.41M-$1.55N/AN/AN/A-30.60%-23.73%-17.34%10/27/2025 (Estimated)WEDXFWestaim-$16.18M-$1.40N/A∞N/A-118.02%-6.03%-5.73%11/11/2025 (Estimated)Latest WEDXF, INSP, LQDA, and PRCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/21/2025Q2 2025WEDXFWestaim-$0.17-$0.01+$0.16-$0.01$1.46 million$10.50 million8/12/2025Q2 2025LQDALiquidia Technologies-$0.43-$0.49-$0.06-$0.49$3.90 million$8.84 million8/6/2025Q2 2025PRCTPROCEPT BioRobotics-$0.41-$0.35+$0.06-$0.35$75.67 million$79.18 million8/4/2025Q2 2025INSPInspire Medical Systems$0.22$0.45+$0.23-$0.12$214.50 million$217.09 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINSPInspire Medical SystemsN/AN/AN/AN/AN/ALQDALiquidia TechnologiesN/AN/AN/AN/AN/APRCTPROCEPT BioRoboticsN/AN/AN/AN/AN/AWEDXFWestaimN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINSPInspire Medical SystemsN/A6.144.84LQDALiquidia Technologies9.842.492.41PRCTPROCEPT BioRobotics0.139.217.86WEDXFWestaimN/A11.4011.40Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINSPInspire Medical Systems94.91%LQDALiquidia Technologies64.54%PRCTPROCEPT BioRobotics89.46%WEDXFWestaimN/AInsider OwnershipCompanyInsider OwnershipINSPInspire Medical Systems4.10%LQDALiquidia Technologies26.50%PRCTPROCEPT BioRobotics6.60%WEDXFWestaim4.21%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINSPInspire Medical Systems1,24629.57 million28.36 millionOptionableLQDALiquidia Technologies5086.09 million63.28 millionOptionablePRCTPROCEPT BioRobotics43055.64 million51.96 millionOptionableWEDXFWestaim733.56 million32.14 millionNot OptionableWEDXF, INSP, LQDA, and PRCT HeadlinesRecent News About These CompaniesWestaim Reports Q2 2025 Results for the Quarter Ended June 30, 2025August 21, 2025 | businesswire.comFinancial Analysis: Westaim (OTCMKTS:WEDXF) & Ecolab (NYSE:ECL)August 21, 2025 | americanbankingnews.comWestaim (OTCMKTS:WEDXF) Sees Large Volume Increase - Should You Buy?August 9, 2025 | marketbeat.comWestaim (OTCMKTS:WEDXF) Shares Down 0.9% - Here's What HappenedAugust 5, 2025 | marketbeat.comAM Best Assigns Credit Ratings to Ceres Life Insurance CompanyJuly 15, 2025 | businesswire.comThe Westaim Corporation Reports Q1 2025 ResultsMay 14, 2025 | businesswire.comCC Capital and Westaim Complete Transaction, Creating Integrated Insurance and Asset Management PlatformApril 3, 2025 | businesswire.comWestaim Announces Receipt of Required Regulatory Approvals in Connection with CC Capital TransactionMarch 27, 2025 | businesswire.comThe Westaim Corporation Announces Normal Course Issuer BidMarch 26, 2025 | businesswire.comThe Westaim Corporation Reports Q4 and Full Year 2024 Results and Update on Timing of Proposed Transactions with CC CapitalMarch 26, 2025 | businesswire.comWestaim completes acquisition of ManhattanLifeFebruary 6, 2025 | insurancebusinessmag.comIWestaim: Transforming Into A Potential Long-Term Compounding MachineJanuary 30, 2025 | seekingalpha.comThe Westaim Corp WEDXDJanuary 14, 2025 | morningstar.comMThe Westaim Corporation Announces Completion of ArrangementJanuary 2, 2025 | businesswire.comWestaim: Stocks Undervalued by Analyst Consensus on TSX-V (WED)December 22, 2024 | theglobeandmail.comThe Westaim Corporation appoints CRODecember 6, 2024 | complianceweek.comCThe Westaim Corporation Files Management Information Circular for Special Shareholders Meeting and Encourages Shareholders to Access Meeting Materials OnlineNovember 27, 2024 | newsfilecorp.comNThe Westaim Corporation Files Management Information Circular for Special Shareholders Meeting and Encourages Shareholders to Access Meeting Materials OnlineNovember 27, 2024 | newsfilecorp.comNCC Capital & Westaim partner on new integrated insurance and asset management platformOctober 11, 2024 | reinsurancene.wsRCC Capital and Westaim to create insurance and asset management platformOctober 9, 2024 | pehub.comWestaim Corporation: A Bargain In The Asset Management WorldSeptember 4, 2024 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeWEDXF, INSP, LQDA, and PRCT Company DescriptionsInspire Medical Systems NYSE:INSP$93.86 +2.40 (+2.63%) Closing price 08/29/2025 03:59 PM EasternExtended Trading$92.75 -1.11 (-1.19%) As of 08/29/2025 05:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.Liquidia Technologies NASDAQ:LQDA$27.68 +0.22 (+0.80%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$27.60 -0.07 (-0.27%) As of 08/29/2025 06:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.PROCEPT BioRobotics NASDAQ:PRCT$40.17 -0.17 (-0.42%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$40.73 +0.56 (+1.39%) As of 08/29/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.Westaim OTCMKTS:WEDXF$20.15 -0.06 (-0.30%) As of 08/29/2025 01:10 PM EasternThe Westaim Corporation is a private equity firm specializing in direct and indirect investments through acquisitions, joint ventures, secondary investments both direct and indirect, fund of fund investments, and other arrangements. For direct investments, the firm invests in early venture, mid venture, late venture, middle market, later stage, mature, emerging growth, PIPEs, and buyout transactions. For fund of fund investments, it seeks to invest in private equity funds, venture capital funds, and hedge funds. The firm seeks to provide long term capital to businesses operating in the global financial services industry. It typically acquires controlling interests in businesses. The firm seeks to acquire debt, equity, or derivative securities of both public and private companies. It invests with the objective of providing its shareholders with capital appreciation and real wealth preservation. The firm seeks to provide its portfolio companies with advisory services including, but not limited to, advice on capital allocation, financing strategy, performance measurement and merger and acquisition support. It also seeks to partner with like-minded providers of third party capital to help supplement the firm's own capital, when completing acquisitions. The firm generally seeks to hold its investments for seven to 15 years. The Westaim Corporation was founded in 1996 and is based in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
